Pharmafile Logo
Pharmafocus logo
Advanced Search

Roche

Showing 15 posts of 710 posts found.

fdaoutsideweb

FDA greenlights Gavreto for advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer in over-12s

December 2, 2020
Research and Development, Sales and Marketing FDA, Gavreto, Roche

The FDA has awarded accelerated approval to Roche and Blueprint Medicines’ Gavreto (pralsetinib) for the treatment of advanced or metastatic …

News

FDA approves Venclexta combo in acute myeloid leukaemia, despite it missing main study goal

October 19, 2020
Sales and Marketing AbbVie, FDA, Roche, Venclexta, pharma

The FDA has given approval to AbbVie and Roche’s jointly-developed BCL-2 inhibitor Venclexta (venetoclax) in combination with azacitidine, decitabine, or low-dose …

News
800px-a_tamiflu_oseltamivir_capsule

Judge allows $1.5 billion Tamiflu stockpiling lawsuit against Roche to go ahead

September 30, 2020
Research and Development Roche, Tamiflu

A Maryland federal judge denied Roche’s motion to throw out a lawsuit that alleges the company defrauded the US and …

News
800px-lt

Roche says its rheumatoid arthritis drug reduces the need for ventilators in coronavirus patients

September 18, 2020
Medical Communications COVID-19, Roche

Roche says that its Actermra/Roactemra drugs reduce the likelihood that coronavirus patients with virus-related pneumonia will need to be put …

News
download_1

Roche to start new trials of Ocrevus to defend multiple sclerosis franchise

September 9, 2020
Research and Development MS, MS drug, Roche

Roche is to begin expanding trials of Ocrevus in multiple sclerosis (MS) patients to defend its MS franchise from its …

News
shutterstock_36423250

China approves its first biosimilar of Roche’s Herceptin in HER2+ cancers

August 18, 2020
Manufacturing and Production, Sales and Marketing China, Henlius, Herceptin, Roche, biosimilar

China’s National Medical Products Administration (NMPA) has given the green light to Shanghai’s Henlius for its biosimilar version of Roche’s …

News
roche

Roche’s entrolizumab disappoints at Phase 3 in moderately to severely active ulcerative colitis

August 11, 2020
Manufacturing and Production, Research and Development Roche, etrolizumab, trial failure, ulcerative colitis

Roche has voiced its disappointment after its investigational therapy etrolizumab showed “mixed results” as a treatment for moderately to severely …

News
fdaoutsideweb

Genentech’s Evrysdi becomes first FDA-approved oral treatment for spinal muscular atrophy

August 10, 2020
Sales and Marketing Evrysdi, FDA, Genentech, Roche, spinal muscular atrophy

Genentech’s Evrysdi (risdiplam) has secured FDA approval for the treatment of spinal muscular atrophy (SMA), making it the first oral therapy …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

July 31, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Roche, UK government, Vaccine, lilly, pharma, top 10

Another week dominated by COVID-19. Among our most popular stories this week, Celltrion’s infliximab biosimilar Remsima has scored approval for …

News
shutter

UCB syncs up with Roche and Genentech in Alzheimer’s drug deal worth a potential $2bn+

July 30, 2020
Research and Development, Sales and Marketing Genentech, Roche, UCB, partnership

UCB Pharma is set to partner up with Roche and Genentech in a development and commercialisation deal focused on its …

News
roche

Roche’s Actemra fails to improve clinical status in COVID-19-associated pneumonia

July 29, 2020
Research and Development Actemra, COVID-19, Roche, pharma

Roche has announced the disappointing news that its therapy Actemra/RoActemra (tocilizumab) failed to improve clinical status to a statistically significant …

News
shutterstock_273326141

Roche and Blueprint extend collaboration with $1.7 billion cancer drug development and commercialisation deal

July 14, 2020
Manufacturing and Production, Research and Development Blueprint Medicines, Cancer, Roche, pralsetinib

Roche and Blueprint Medicines have come together in a $1.7 billion development and commercialisation partnership focused on precision therapy pralsetinib …

News
tecentriq

Roche’s Tecentriq fails to hit main Phase 3 goal in front-line ovarian cancer

July 13, 2020
Research and Development, Sales and Marketing Genentech, Roche, ovarian cancer, tecentriq

Roche subsidiary Genentech has revealed that its immunotherapy Tecentriq (atezolizumab), combined with Avastin (bevacizumab), paclitaxel and carboplatin, fell short of …

News
roche

Roche’s Phesgo combo secures US approval for metastatic HER2-positive breast cancer

June 30, 2020
Manufacturing and Production, Sales and Marketing FDA, Phesgo, Roche, US, breast cancer

The FDA has awarded marketing authorisation in the US to Roche’s Phesgo, a combination of subcutaneously injected Herceptin (trastuzumab) with …

News

Roche’s Tecentriq improves pathological complete response in triple-negative breast cancer at Phase 3

June 19, 2020
Medical Communications, Research and Development Cancer, Genentech, Roche, breast cancer, tecentriq

 

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025